Masayuki Uchi1, Tsutomu Saji, Takashi Harada. 1. Department of Physical Medicine and Rehabilitation, School of Medicine, Faculty of Medicine, Toho University, Tokyo. masayuki@med.toho-u.ac.jp
Abstract
OBJECTIVES: To evaluate cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension who had severe heart failure. METHODS: The subjects comprised 11 men and 13 women aged 5 to 37 years old with idiopathic pulmonary arterial hypertension, who received cardiopulmonary rehabilitation following the start of continuous intravenous prostacyclin administration between January 1999 and September 2003. Fifteen patients were categorized in New York Heart Association (NYHA) functional class-III and 9 were class-IV on admission. Patients received cardiopulmonary rehabilitation consisting of breathing exercise, training of upper extremity muscles, gait training, bicycle ergometer training, and treadmill walking for 30 to 60 min per day, 5 days a week. Cardiothoracic ratio, NYHA class, heart rate, pulse oximeter saturation, plasma levels of human atrial natriuretic peptide and brain natriuretic peptide, tricuspid regurgitation, and right ventricular myocardial index (RV Tei index) were evaluated by echocardiography, lower extremity muscle strength, ambulation ability, Barthel index, and 6-minute walking distance at the beginning and end of cardiopulmonary rehabilitation. RESULTS: The average period of cardiopulmonary rehabilitation was 6.7 weeks. There was no deterioration in cardiothoracic ratio, human atrial natriuretic peptide, brain natriuretic peptide levels, tricuspid regurgitation, RV Tei index and pulse oximeter saturation. The results also showed decreased heart rate at rest (p = 0.007), and improved NYHA class (p = 0.010), lower extremity strength (p < 0.001), ambulation ability (p < 0.001), Barthel index (p < 0.001), and 6-minute walking distance (p = 0.001). CONCLUSIONS: Cardiopulmonary rehabilitation is safe and effective for idiopathic pulmonary arterial hypertension patients in NYHA class-III and IV during intravenous prostacyclin infusion without deterioration of cardiac functions, despite the conventional contraindication.
OBJECTIVES: To evaluate cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension who had severe heart failure. METHODS: The subjects comprised 11 men and 13 women aged 5 to 37 years old with idiopathic pulmonary arterial hypertension, who received cardiopulmonary rehabilitation following the start of continuous intravenous prostacyclin administration between January 1999 and September 2003. Fifteen patients were categorized in New York Heart Association (NYHA) functional class-III and 9 were class-IV on admission. Patients received cardiopulmonary rehabilitation consisting of breathing exercise, training of upper extremity muscles, gait training, bicycle ergometer training, and treadmill walking for 30 to 60 min per day, 5 days a week. Cardiothoracic ratio, NYHA class, heart rate, pulse oximeter saturation, plasma levels of human atrial natriuretic peptide and brain natriuretic peptide, tricuspid regurgitation, and right ventricular myocardial index (RV Tei index) were evaluated by echocardiography, lower extremity muscle strength, ambulation ability, Barthel index, and 6-minute walking distance at the beginning and end of cardiopulmonary rehabilitation. RESULTS: The average period of cardiopulmonary rehabilitation was 6.7 weeks. There was no deterioration in cardiothoracic ratio, human atrial natriuretic peptide, brain natriuretic peptide levels, tricuspid regurgitation, RV Tei index and pulse oximeter saturation. The results also showed decreased heart rate at rest (p = 0.007), and improved NYHA class (p = 0.010), lower extremity strength (p < 0.001), ambulation ability (p < 0.001), Barthel index (p < 0.001), and 6-minute walking distance (p = 0.001). CONCLUSIONS: Cardiopulmonary rehabilitation is safe and effective for idiopathic pulmonary arterial hypertensionpatients in NYHA class-III and IV during intravenous prostacyclin infusion without deterioration of cardiac functions, despite the conventional contraindication.
Authors: Joshua G Woolstenhulme; Andrew A Guccione; Jeffrey E Herrick; John P Collins; Steven D Nathan; Leighton Chan; Randall E Keyser Journal: J Cardiopulm Rehabil Prev Date: 2019-03 Impact factor: 2.081
Authors: Leighton Chan; Lisa M K Chin; Michelle Kennedy; Joshua G Woolstenhulme; Steven D Nathan; Ali A Weinstein; Gerilynn Connors; Nargues A Weir; Bart Drinkard; James Lamberti; Randall E Keyser Journal: Chest Date: 2013-02-01 Impact factor: 9.410
Authors: Louise Ganderton; Sue Jenkins; Kevin Gain; Robin Fowler; Peta Winship; Dianne Lunt; Eli Gabbay Journal: BMC Pulm Med Date: 2011-05-23 Impact factor: 3.317
Authors: Mary Beth Brown; Attie Kempf; Catherine M Collins; Gary M Long; Matthew Owens; Shikha Gupta; Yaron Hellman; Vincent Wong; Mark Farber; Tim Lahm Journal: Pulm Circ Date: 2018 Jan-Mar Impact factor: 3.017